Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ambrx, a San Diego-China ADC Company, Acquired by J&J for $2 Billion

publication date: Jan 9, 2024

San Diego’s Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion, a 105% premium to its previous closing price. Ambrx is a US-China company that is developing a portfolio of four antibody drug conjugates. JNJ said it would accelerate the Phase I/II study of ARX517 in advanced prostate cancer, while advancing Ambrx’s entire ADC pipeline. Ambrx has two China subsidiaries, and it has sold China rights for two of its candidates to China biopharmas. In 2015, Ambrx was bought by a consortium of four China companies, though none of them seem active in Ambrx. More details....

Stock Symbol: (NSDQ: AMAM)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here